<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article184</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/PEITHO" style="display:block; margin-bottom:10px;">PEITHO Original</a></li>
<h2><strong>PEITHO</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Tenecteplase in Normotensive Patients with Pulmonary Embolism". The New England Journal of Medicine. 2014. 370(15):1402-1411. PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In normotensive patients with intermediate-risk pulmonary embolism, does treatment with tenecteplase in addition to anticoagulation improve clinical outcomes?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In normotensive patients with intermediate-risk pulmonary embolism, tenecteplase treatment reduced the primary composite outcome of death or hemodynamic decompensation compared to placebo, but increased the risk of major hemorrhage and stroke.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the last knowledge update, specific guidelines reflecting the results of this trial were not referenced.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, placebo-controlled randomized trial <br/>
- N=1,005 participants with intermediate-risk PE<br/>
- Tenecteplase + heparin (n=506)<br/>
- Placebo + heparin (n=499)<br/>
- Setting: 76 sites in 13 countries<br/>
- Enrollment: November 2007 to July 2012<br/>
- Follow-up: 30 days<br/>
- Analysis: Intention-to-treat<br/>
- Primary outcome: Death or hemodynamic decompensation within 7 days<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria:<br/>
- Age ≥18 years<br/>
- Confirmed acute PE with symptom onset within 15 days<br/>
- Echocardiography or CT showing right ventricular dysfunction<br/>
- Positive cardiac troponin I or T test<br/>
<br/>
Exclusion Criteria:<br/>
- Systolic blood pressure &lt;90 mm Hg or drop ≥40 mm Hg for &gt;15 minutes<br/>
- Active internal bleeding<br/>
- Ischemic stroke within preceding 2 months<br/>
<br/>
Baseline Characteristics:<br/>
- Median age: 70 years<br/>
- Female: 44.5%<br/>
- Normotensive at randomization<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Tenecteplase: single weight-based intravenous bolus (30-50 mg)<br/>
- Placebo: intravenous bolus of the same volume and appearance as tenecteplase<br/>
- Both groups received unfractionated heparin according to protocol<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes:<br/>
- Death or hemodynamic decompensation within 7 days: 2.6% (tenecteplase) vs. 5.6% (placebo); OR 0.44 [95% CI, 0.23 to 0.87]; P=0.02<br/>
<br/>
Secondary Outcome:<br/>
- Death within 7 days: 1.2% vs. 1.8%; P=0.42<br/>
- Death within 30 days: 2.4% vs. 3.2%; P=0.42<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Study not powered to detect differences in death rates, which were infrequent.<br/>
- Hemodynamic decompensation had a broad definition, including persistent hypotension without overt clinical compromise.<br/>
- Intracranial and major bleeding rates may limit the practical use of fibrinolytic therapy in intermediate-risk PE.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by Programme Hospitalier de Recherche Clinique in France, the Federal Ministry of Education and Research in Germany, and a grant from Boehringer Ingelheim. <br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- Konstantinides, Stavros V., et al. "Fibrinolysis for patients with intermediate-risk pulmonary embolism." New England Journal of Medicine 370.15 (2014): 1402-1411.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
